| InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the pricing of an underwritten public offering of 8,281,574 shares of its common stock, offered at a price to the public of $2.10 per share, for gross proceeds of approximately $17.4 million. Net proceeds to InVivo, after deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $15.7 million. InViv...continued NVIV |
Thursday, February 16, 2012
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment